Inactive Instrument

PCAS Share Price

PCA

FR0000053514

PCAS specializes in developing, manufacturing, and marketing fine and specialty chemicals. Sales are distributed by family of products as follows: - synthesized pharmaceutical products (63.5%); - fine chemicals (36.5%): technical fluids and additives for the lubricant industry, chemical additive synthesis. The group also offers photochemical and new technology products (photosensitive materials, photo-initiators, and polymers for photography, reprography, and micro-electronics). At the end of 2022, the group had 7 production sites located in France (5), Canada and Finland. France accounts for 76% of net sales.

Employees

1,178

Sector

Pharmaceuticals

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

As early as today, start finding the best investment opportunities!

09/02/24	Orapi: takeover bid reopens on February 12
02/02/24	Orapi: 3.15 million shares tendered to the takeover bid
22/12/23	Orapi: takeover bid opens on December 27
18/12/23	PCAS: 200 ME capital increase
03/11/23	PCAS: OPAS to start this Friday
24/10/23	PCAS Announces the Consolidated Net Sales Results for the Month of September 30, 2023	CI
16/10/23	Progyny, Inc. : Want to have a baby?
07/09/23	PCAS: Seqens launches minority share offer
05/09/23	PCAS SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI
27/07/23	PCAS SA Reports Consolidated Sales Results for the Period Ended June 30, 2023	CI
31/05/23	DIC Corporation completed the acquisition of PCAS Canada Inc. from PCAS SA.	CI
25/05/23	PCAS: sale of Canadian subsidiary confirmed
25/05/23	PCAS to Divest Canadian Arm to Japan's DIC	MT

24/10/23	PCAS: Net Sales as of September 30, 2023	GL
06/09/23	PCAS: RESULTS AS OF JUNE 30, 2023	GL
27/07/23	Pcas: Net sales as of June 30, 2023	GL
25/05/23	PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation	GL
02/05/23	PCAS enters into exclusive negotiations with DIC Corporation following receipt of an offer for the acquisition of its Canadian subsidiary, PCAS Canada Inc.	GL

09/02/24	Orapi : l'OPA réouvre le 12 février
02/02/24	Orapi : 3,15 millions d'actions apportées à l'OPA
05/01/24	Progyny, Inc.: ¿Quieres tener un bebé?
22/12/23	Orapi : l'OPA démarre le 27 décembre
18/12/23	PCAS : augmentation de capital de 200 ME

Manager	Title	Age	Since
Gildas Barreyre CEO	Chief Executive Officer	43	02/05/2025
Eric Moissenot DFI	Director of Finance/CFO	-	-
Gérard Guillamot CTO	Chief Tech/Sci/R&D Officer	-	28/02/1999

Director	Title	Age	Since
Jacqueline Lecourtier BRD	Director/Board Member	74	28/02/2014
Janine Cossy BRD	Director/Board Member	-	-

PCAS Share Price

Stocks

PCA

FR0000053514

Pharmaceuticals

Latest news: PCAS

Press Releases: PCAS

News in other languages: PCAS

Managers and Directors: PCAS

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCAS	-.--%	-.--%	-	-	125M
ELI LILLY AND COMPANY	+3.69%	+9.87%	+58.43%	+119.22%	1,106B
JOHNSON & JOHNSON	+1.88%	+4.12%	+33.63%	+69.19%	612B
ABBVIE INC.	+1.82%	+5.26%	+24.44%	+97.48%	500B
ROCHE HOLDING AG	+2.58%	+8.37%	+38.71%	+63.14%	367B
MERCK & CO., INC.	+2.93%	+4.43%	+71.77%	+44.42%	354B
NOVARTIS AG	+1.85%	+6.04%	+21.47%	+49.17%	286B
ASTRAZENECA PLC	+1.76%	+6.07%	+0.43%	+20.98%	256B
AMGEN INC.	+2.53%	+5.47%	+43.54%	+56.17%	230B
GILEAD SCIENCES, INC.	+1.78%	+5.48%	+26.74%	+100.55%	190B
Average	+2.00%	+2.13%	+35.46%	+68.93%	433.35B
Weighted average by Cap.	+2.49%	+2.30%	+40.60%	+80.30%